1 / 32

Title:

Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery. Title:. Papillary thyroid carcinoma (PTC) is the most common malignancy arising from thyroid follicular cells. Although PTC frequently

devaki
Download Presentation

Title:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Is the BRAFV600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery Title:

  2. Papillary thyroid carcinoma (PTC) is the most common malignancy arising from thyroid follicular cells. Although PTC frequently metastasizes to regional lymph nodes, it generally shows an indolent character and slow growth. However, PTCs showing certain characteristics have poor prognosis and are classified into high-risk groups. There are several classification systems for evaluation of the progression of thyroid carcinoma. Introduction:

  3. These systems are mainly used for the identification of patients with a poor prognosis to ensure that they receive additional treatment, such as radioiodine ablation and more frequent follow-up monitoring. However, these classification Systems include postoperative data for guidance with regard to the extent of initial surgical resection

  4. Moreover, many patients (80% or more) currently diagnosed with thyroid cancer have small, localized PTC but may receive aggressive treatment because their risk of recurrence and mortality cannot be reliably predicted preoperatively

  5. By contrast, some clinicians in Japan have suggested that patients with a solitary small (1.0 cm) PTC may require observation only, if there is no evidence of lymph node Metastasis or multifocal disease on neck ultrasound.Although the death rate from thyroid cancer has not changed,

  6. The recently discovered activating mutation in the gene for the B type Rafkinase, BRAF, is the most common genetic alteration in thyroid cancer.Themost common activating BRAF mutation, a thymidine-to-adenine Transversion at nucleotide 1799, resulting in a valineto Glutamic acid substitution at amino acid 600 (V600E), has Been observed in approximately 29% to 83% of PTCs.Theprevalence of this mutation has been found to differ According to PTC subtype.

  7. Although several studies have reported that this mutation is related to poor prognosis and reflects aggressive Clinicopathologic features in patients with PTC, especially in Western countries, other studies have found no statistically significant association between the BRAFV600E mutation and poor prognosis and Aggressive Clinicopathological characteristics, including frequent lymph node metastasis in this disease, especially in eastern countries.

  8. To date, the UICC/AJCC TNM staging system has been the most widely adopted classification systems for evaluation of the prognosis of thyroid carcinoma. Therefore, we evaluated clinicopathologicfactors that were suspicious for associationWith poor prognosis based on TNM staging And analyzed the association between the BRAFV600E mutation and these Clinicopathologic factors

  9. Thyroid tumor tissues were sampled from 424 patients with PTC who underwent various thyroidectomyfrom September 2008 to December 2009 at the Department of Surgery, Seoul St. Mary’s Hospital, Seoul, Korea. We Obtained informative results for 424 patients, and these patients were enrolled in this study. These 424 patients included 79 men and 345 women, and the mean age of patients at surgery was 46.9 ± 12.4 (17 to 76) years. Materials and Methods: patients

  10. Total or near total thyroidectomy was performed for 367 patients (86.8%), whereas the remaining patients underwent more limited thyroidectomy, such as subtotal (23 patients), completion (5 patients) thyroidectomy, and lobectomy (29 patients). Central compartment dissection alone was performed For 415 patients (97.9%), and modified radical neck dissection, including central neck dissection, was performed on 9 patients (2.1%).

  11. We investigated lymph node metastasis in 424 patients with PTC who underwent thyroidectomy and neck dissection. Of these patients, lymph node metastasis occurred in 205 (48.3%) patients. (Table 1) Table 2 shows the relationship between lymph node metastasis and clinicopathological features that were suspected to have a prognostic effect to PTC. Lymph node metastasis didnot differ significantly between patients with and without the BRAFV600Emutation. Results

  12. We then performed multivariate analysis. Table3 Shows that age <45, size of cancer >1 cm, extrathyroidal extension, and galectin3 expressionwere independently associated with lymph node metastasis of PTC. We investigated the BRAFV600Emutation in 424 patients with papillary thyroid cancer. Of these patients, 335 (79.0%) Patients showed the BRAFV600Emutation.

  13. Table 4 shows the relationship between the BRAFV600Emutation and Clinicopathologic features, including the Metastasis, Patient Age, Completeness of resection, local Invasion and Tumor Size (MACIS) score, which was identified as a reliable prognostic predicting value.

  14. The incidence of the BRAFV600E mutation was notlinked to the MACIS score, age, sex, or cancer size on univariateanalysis. Extrathyroidal extension and galectin3 expression, multifocality, And variant of PTC were associated with the BRAFV600E mutation. Extrathyroidal extension is an independent factor affecting the BRAFV600Emutation on multivariate analysis(Table 5).

  15. The incidence of classic PTC was higher at 84.3% Than the follicular variant of PTC at 7.6%, and, additionally, there was an oncocytic Type and 36 (8.7%) mixed types. The prevalence of the BRAFV600E mutation in the follicular variant of PTC was lower at 62.5%, respectively, than that of classic PTC at 79.7%.

  16. This study shows that the BRAFV600E mutation is not associated with a high-risk MACIS score and lymph node metastasis. However, the BRAFV600Emutation differed Significantly between patients with and Without extrathyroidal extension. Multivariate analysis showed that Extrathyroidal extension is independently associated with the BRAFV600E mutation. Comments

  17. These findings are not consistent with previous reports, particularly in Westernareas.However, a recent study in Japan showed that the BRAFV600E mutation did Notshow any relationship with prognostic factors, including lymph node metastasis.Inaddition, other study groups in Korea have reported that age distribution, sex ratio,extrathyroid extension, multifocality, and lymph node metastasis did not differ significantly between patients with and without the BRAFV600E mutation.

  18. In our study population, age< 45 and malesex,size Of cancer ≥1 cm, extrathyroidal extension, galectin3expression,andmultifocality were associated with lymph node metastasis of PTC.

  19. multivariate analysis showed that extrathyroidalextension is independently associated with the BRAFV600Emutation. The Extrathyroidal extension is one of the risk factors of lymph node metastasis in our study, and the other authors have reported it.The route for metastasis and locoregionalinvasion preferentially occurs by lymphatic vessels.In our study, the BRAFV600E Mutation is notassociated with lymphatic invasion (Table 4).

  20. Therefore, we believe that the BRAFV600Emutation Does not affect lymph node metastasis directly. However, the BRAFV600E mutation may affect lymph node metastasis indirectly because it is Associated with extrathyroidal extension independently.

  21. The BRAFV600Emutation is the most common genetic alteration observed in thyroid cancer and occurs in 36% to 65% of PTCs in Western countries. However, the BRAFV600Emutation was found in 79% of patients in our study. This frequency of the BRAFV600E mutation is higher than that of other studies. The BRAFV600E Mutation of PTC in Korea, a country where iodineintakeis very high, is Reported to be highly prevalent (52%–87%) compared with Western countries.Thismay be Because most PTCs in Korea are the classictype.

  22. Our study cannot show the association between the prognosis of PTC and the presence of the BRAFV600Emutation; however, we found that the BRAFV600E mutation is not associated with a high MACIS score and lymph node metastasis, cancer size, and sex in our study group. A long-term follow-up study is needed to identify the association between the prognosis of PTC and the BRAFV600Emutation.

  23. Although there are only a few published studies of interracial and regional differences between the BRAFV600E mutation and the prognosis of PTC, it appears to be present in the difference between eastern and western countries.

  24. We showed that the BRAFV600Emutation is commonly found in the Korean Population rather than in Western populations; however, it is not related to a high-risk MACIS score and several high-risk clinicopathologicfactors, including lymph node metastasis. However, it is Related to a few High risk clinicopathologicfactors including multifocality And extrathyroidal extension. Therefore, it is not clear that The BRAFV600E mutation is useful for the prediction of a poor prognosis of PTC. Conclusions

  25. In addition, although the BRAFV600E Mutation may play some role in the development of local carcinoma, it is not appropriate for determination of the extent of surgical treatment or postoperative treatment and planning of follow-up monitoring in PTC according to the existence of the BRAFV600Emutation.

More Related